MicroTransponder reports first commercial implantation of its stroke rehab neurostim system

The Vivistim paired VNS system for chronic ischemic stroke rehabilitation [Image courtesy of MicroTransponder]MicroTransponder (Austin, Texas) recently announced the first commercial implantation of its Vivistim paired VNS system for chronic ischemic stroke rehabilitation.

Dr. Charles Y. Liu, director of the University of Southern California Neurorestoration Center, and Dr. Jonathan J. Russin, director of the USC Neuro Revascularization Center, successfully placed the small Vivistim device under the skin of Rosa Maria Villalpando’s upper left chest area during an outpatient procedure. The news, reported in a May 11 news release, comes nearly a year after MicroTransponder announced FDA approval of the Vivastim system.

“We are proud that the Vivistim System is reviving hope for stroke survivors and addressing an unmet need for those who have chronic impairment,” MicroTransponder CEO Richard Foust said in a news release. “Stroke survivors whose hand and arm fun…

Read more
  • 0

Women may have more adverse events with left atrial appendage occlusion devices than men

Left atrial appendage occlusion (LAAO) devices on the market include Abbott’s Amplatzer Amulet (left) and Boston Scientific’s Watchman (right). [Images courtesy of Abbott and Boston Scientific]Women appear more likely than men to experience adverse events or lengthened hospital stays from left atrial appendage occlusion (LAAO) devices, the FDA announced today.

In a letter to health care providers, the FDA said researchers have yet to determine the reason for the difference — and that it is working with device makers to understand the cause.

Get the full story on our sister site Medical Design & Outsourcing. 

Read more
  • 0

Women may have more adverse events with left atrial appendage occlusion devices than men

Left atrial appendage occlusion (LAAO) devices on the market include Abbott’s Amplatzer Amulet (left) and Boston Scientific’s Watchman (right). [Images courtesy of Abbott and Boston Scientific]

Women appear more likely than men to experience adverse events or lengthened hospital stays from left atrial appendage occlusion (LAAO) devices, the FDA announced today.

The FDA in its letter to health care providers said that researchers have yet to determine the reason for the difference — and that it is working with device makers to determine the cause.

For now, FDA officials still think that the benefits outweigh the risks when it comes to using LAAO devices such as Abbott’s Amplatzer Amulet and Boston Scientific’s Watchman and Watchman FLX to prevent people with atrial fibrillation from experiencing strokes.

The FDA advised health providers to continue monitoring people with LAA…

Read more
  • 0

Rapid Medical raises $50M to support its minimally invasive stroke treatments

Rapid Medical has completed an oversubscribed Series D financing worth $50 million, with money slated to support rapid worldwide commercialization of the Yokeam, Israel–based company’s minimally invasive stroke treatment tech.

The money raised comes on the heels of FDA clearance of the company’s Tigertriever revascularization device to treat ischemic stroke. Touted as a new class of clot retriever, the device includes intelligent control that allows neuro-interventionalists to better remove blood clots and restore blood flow to the brain following an ischemic event.

Rapid Medical also has the Tigertriever 13, which has a CE mark but is not yet FDA-cleared. The Tigertriever 13 is the smallest device it the company’s Tigertriever portfolio. The company describes it as the only clot retriever in the world indicated to remove clots from more distant areas in the brain.

“We’ve revolutionized intravascular devices by providing physicians with…

Read more
  • 0